OCC Trading, page-1256

Orthocell is a Perth-based biotech company focused on products aimed at treating musculoskeletal diseases and peripheral nerves. While much of the Orthocell branding material uses the term ‘regenerative medicine’, this description often invokes thoughts of stem cell therapies – although this is not the approach Orthocell takes. Orthocell has two products in market from their proprietary CelGroTM Platform of collagen medical devices – an absorbable collagen membrane used to augment and guide the repair of bone (marketed as Striate+TM) and a collagen membrane to repair nerve injuries (marketed as RemplirTM) and return function to paralysed upper limbs. Orthocell also markets an approved autologous cell therapy in Australia (using the patient’s own cells) aimed at treating damaged cartilage (OrthoACITM).In July 2022, Orthocell signed a global 25-year exclusive licence and distribution agreement with BioHorizons Implant Systems Inc. (BioHorizons), one of the largest dental implant companies in the world, for Striate+TM. Orthocell received AUD$21.5m (USD $14.8m) in consideration of this agreement. We anticipate BioHorizons will supply ~ 2,000 units in FY23, increasing to 100,000+ units per annum by FY28.In March 2022, Orthocell received market approval by the TGA in Australia for its RemplirTM peripheral nerve repair device. We expect penetration into the market will begin at around 3% (~300 units) in FY23 and ramp up to 30% (~3,000 units) over ten years (with only one other comparable collagen wrap device available). The company is running a clinical trial using RemplirTM for a future FDA regulatory application.

Aloha.